Evidence map›Paper›PMID 38272842›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2024

Myositis-Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality.

Matthew A Sherman, Payam Noroozi Farhadi, Katherine Pak, Edward P Trieu, Kakali Sarkar, Ira N Targoff, Megan L Neely, Andrew L Mammen, Lisa G Rider, Childhood Myositis Heterogeneity Collaborative Study Group

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00017914 (Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00017914 recruitingnot on this map

Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies

TypeobservationalSponsorNational Institute of Environmental Health Sciences (NIEHS)Ran1995Enrolled1,200ConditionsDermatomyositis, Polymyositis, Inclusion Body Myositis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Matthew A ShermanNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.ORCID 0000-0002-5448-1538
Payam Noroozi FarhadiNational Institute of Environmental Health Sciences, NIH, Bethesda, Maryland.
Katherine PakNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Edward P TrieuOklahoma Medical Research Foundation, Oklahoma City.
Kakali SarkarNational Institute of Environmental Health Sciences, NIH, Bethesda, Maryland.
Ira N TargoffVeterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City.
Megan L NeelyDuke University School of Medicine, Durham, North Carolina.
Andrew L MammenNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, and Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3732-3252
Lisa G RiderNational Institute of Environmental Health Sciences, NIH, Bethesda, Maryland.ORCID 0000-0002-6912-2458
Childhood Myositis Heterogeneity Collaborative Study Group
National Institutes of Health · USCollaborative Research Group · AUDuke University · USJohns Hopkins University · USOklahoma Medical Research Foundation · USUniversity of Oklahoma Medical Center · US

Funding

Environmental/genetic Risk Factors and Pathogenesis of Autoimmune DiseaseZIAES101074 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$34.6M
Muscle Disease UnitZIAAR041203 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI MAMMEN, ANDREW · 2015 to 2025
$19.7M
Assessment, Therapy and Prevention Of Autoimmune DiseaseZIAES101081 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$17.6M
Assessment, Therapy and Prevention Of Autoimmune DiseaseZ01ES101081 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MILLER, FREDERICK · 2002 to 2008
$2.2M
Intramural NIH HHS Z01 ES101081Intramural NIH HHS ZIA AR041203Intramural NIH HHS ZIA ES101074Intramural NIH HHS ZIA ES101081NIAMS NIH HHS ZIA-AR-041203NIEHS NIH HHS ZIA-ES-101074NIEHS NIH HHS ZIA-ES-101081NIH
6 · The paper itself

Abstract

objectiveMyositis-associated autoantibodies (MAAs) have been associated with overlap myositis, certain disease manifestations such as interstitial lung disease (ILD), and worse prognosis in the idiopathic inflammatory myopathies. MAAs overall remain largely uncharacterized in patients with juvenile-onset myositis. Moreover, it is unknown whether the number of MAAs is associated with disease severity.

methodsPatients with juvenile myositis in cross-sectional natural history studies who underwent testing for myositis autoantibodies were included. Demographics, myositis autoantibodies, clinical characteristics, medications received, and outcomes of those with and without MAAs were compared. Multivariable logistic regression was performed to determine whether the number of MAAs detected was associated with severe disease features.

resultsAmong 551 patients, 36% had an MAA and 13% had more than one MAA. Among those who were MAA positive, there was a higher frequency of overlap myositis (18% vs 5.9%, P < 0.001). MAA positivity was associated with certain clinical features, including Raynaud phenomenon (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.41-4.28) and ILD (OR 3.43, 95% CI 1.75-6.96), as well as a chronic disease course (OR 1.72, 95% CI 1.10-2.72) and mortality (OR 3.76, 95% CI 1.72-8.43). The number of MAAs was also associated with mortality (OR 1.83, 95% CI 1.16-2.86).

conclusionMAAs were prevalent in a large cohort of patients with juvenile myositis. ILD, refractory disease, and mortality were associated with MAA positivity. Prospective studies are needed to determine whether early detection of MAAs may lead to improved outcomes for patients with juvenile myositis.

Indexed as

AutoantibodiesMyositisAdolescentChildChild, PreschoolCross-Sectional StudiesDermatomyositisFemaleHumansLogistic ModelsLung Diseases, InterstitialMaleRaynaud DiseaseSeverity of Illness IndexAutoantibodies

Identifiers

PMID38272842
PMCPMC11136598
OpenAlexW4391238295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.